CAJ | 학술논문

多发性骨髓瘤(MM)是浆细胞恶性克隆性疾病,自体干细胞移植(ASCT)的加入,增加了大剂量化疗在MM治疗中的优势,使部分患者达到长期生存.即使在靶向新药时代ASCT仍可以明显提高治疗的反应率.靶向新药在ASCT前后联合应用,可辅助提高ASCT的疗效,这是目前使用靶向新药的趋势,但其仍不能取代ASCT在MM治疗中的地位.研究更为合理、有效、低毒的治疗方案是今后的方向.
다발성골수류(MM)시장세포악성극륭성질병,자체간세포이식(ASCT)적가입,증가료대제양화료재MM치료중적우세,사부분환자체도장기생존.즉사재파향신약시대ASCT잉가이명현제고치료적반응솔.파향신약재ASCT전후연합응용,가보조제고ASCT적료효,저시목전사용파향신약적추세,단기잉불능취대ASCT재MM치료중적지위.연구경위합리、유효、저독적치료방안시금후적방향.
Multiple myeloma (MM) is malignant plasma cell clonal disease.Autologous stem cell transplantation (ASCT) strengthen the advantages of the high-dose chemotherapy in treatment of MM,which achieves long-term survival in some patients.Even in the era of targeted novel agents,ASCT can still obviously increase the response rate of treatment.To improve the therapeutic efficacy,targeted novel agents were administrated before and after ASCT.However,targeted novel agents still cannot replace ASCT therapy in the treatment of MM.The direction of future research is to find more reasonable,effective and low toxic treatment.